Overview of Tai Le

Property	Description
Active Ingredient	Terazosin hydrochloride
Form	Oral capsule, Tablet
Pharmacological Class	Selective Alpha-1 Adrenergic Antagonist (Alpha-Blocker)
Origin	Synthetic (Quinazoline derivative)
Route	Oral

Tai Le is the trade name for a prescription-only medication containing the active ingredient Terazosin hydrochloride, which is a single-entity drug product. This compound is a synthetic quinazoline derivative, a type of small molecule delivered for oral administration in the form of a capsule or tablet. The identity of this medication is defined by its precise chemical structure and its inclusion within the antiadrenergic group of agents.

Pharmacological Classification and Dual Action

Terazosin is pharmacologically classified as a selective alpha-1 adrenergic antagonist, commonly known as an alpha-blocker. This designation means the drug acts by binding to and blocking the alpha1 receptors found predominantly on the smooth muscle cells of blood vessels and within the lower urinary tract, including the prostate and bladder neck. The effect of this blockade is the prevention of constricting signals, leading to the relaxation and widening of the smooth muscle tissue.

The essential function of Terazosin is to reduce smooth muscle tone, a property that is clinically recognized for its ability to reduce systemic vascular resistance. This capability establishes the drug's dual benefit: it helps lower blood pressure by easing the flow of blood through dilated vessels and, concurrently, improves the passage of urine by decreasing urethral obstruction. The drug's action is characterized by its systemic effect on muscular resistance.

Regulatory References

Terazosin MedlinePlus Drug Information

What side effects are possible with Tai Le?

Possible Side Effects and Safety Information

The safety profile for Tai Le, as documented by government regulatory agencies, details both commonly occurring adverse events and specific serious risks.

Serious and Clinically Significant Adverse Reactions

The official labeling includes a critical warning regarding the potential for QT prolongation, which is an abnormality in the heart's electrical rhythm. This change can lead to a rare but life-threatening ventricular arrhythmia known as torsades de pointes, which may result in sudden cardiac death. Other serious events reported include severe hypersensitivity reactions like anaphylaxis and the development of Clostridioides difficile-associated diarrhea (CDAD) or colitis.

Adverse Reactions by Body System and Frequency

The safety information classifies adverse reactions across several system-organ classes. Gastrointestinal effects are commonly reported and include symptoms such as diarrhea, nausea, and abdominal pain. Less common effects involve the nervous system (e.g., nervousness) and hepatic system (e.g., cholestatic hepatitis). Events affecting the ear or hearing, such as hearing loss, have also been documented in the regulatory data.

Classification	Examples of Documented Adverse Reactions
Cardiovascular/Serious	QT prolongation, Torsades de pointes
Gastrointestinal	Diarrhea, Nausea, Abdominal pain, CDAD
Hypersensitivity	Anaphylaxis

Safety Restrictions and Limitations

The drug is contraindicated in patients with a known history of QT prolongation, uncontrolled low potassium levels (hypokalemia), or when taken concomitantly with certain medications that are known to prolong the QT interval or are strong inhibitors of the CYP3A4 enzyme. Regulatory documents also include population-specific safety notes; for instance, animal studies have shown potential adverse effects on embryonic development, which indicates a consideration of potential risk for use during pregnancy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Tai Le (Terazosin) overdose is defined by the drug’s profound effects on the cardiovascular system, requiring immediate medical intervention.

Documented Overdose Manifestations

Feature	Official Regulatory Statement
Documented overdose presentations	Primarily characterized by symptoms resulting from excessive lowering of blood pressure, including profound hypotension, dizziness, syncope (fainting), and reflex tachycardia (rapid heart rate).
Physiological systems affected	Primarily the cardiovascular system, leading to hemodynamic instability and potential cardiovascular collapse.
Population-specific overdose notes	Overdose effects (severe hypotension/syncope) may be more pronounced in geriatric populations and those in a volume-depleted state.

Emergency Actions and Supportive Measures

Official regulatory documents mandate specific actions in case of suspected over-exposure:

When immediate medical help is required: Urgent attention is necessary immediately upon suspected overdose, especially if symptoms like syncope, seizure, trouble breathing, or collapse occur.
Emergency-response statements: Seek immediate emergency medical attention, or contact a Poison Control Centre or hospital emergency department immediately, even if no severe symptoms are initially present.
Supportive treatment: Management is symptomatic and supportive. Procedures described include placing the patient in the supine position (lying down) and administering volume expansion with intravenous fluids.
Antidote status: No specific antidote is known for Terazosin toxicity. Vasopressors may be used as a supportive measure to maintain physiologic blood pressure.

The overdose profile is strictly defined by the risk of severe and life-threatening hemodynamic consequences. Continuous monitoring may be required, and the absence of a specific counter-agent dictates immediate emergency support procedures to manage the resultant profound low blood pressure.

Therapeutic Uses of Tai Le

Quick Facts

Acute Heroin Withdrawal: May be utilized to help manage and reduce the severity of symptoms associated with moderate-to-severe acute heroin withdrawal syndrome.

Tai Le (Tai-Kang-Ning capsule) is a traditional Chinese herbal medicine formula that may be considered for specific therapeutic contexts. The primary application of this formulation involves addressing the acute physical symptoms of substance dependence.

The herbal mixture is administered in a regimen intended to support individuals during the difficult period of acute heroin withdrawal. The formula may serve to mitigate the intensity of the associated withdrawal symptoms in patients experiencing moderate to severe forms of the syndrome. It is generally observed to have a supportive role in reducing the discomfort of physical dependency, aligning with traditional approaches focused on symptom management.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Tai Le

The eligibility for Tai Le (Terazosin hydrochloride) is strictly defined by regulatory labeling, detailing specific populations for whom use is permitted, restricted, or prohibited.

Absolute Contraindications

Use is contraindicated (must not be used) in patients with a known hypersensitivity to terazosin, other quinazoline derivatives (such as prazosin), or any excipients in the formulation. The medicine is also strictly prohibited for individuals with a history of micturition syncope (fainting associated with urination).

Age-Related and Condition-Based Restrictions

Use is not recommended in children and adolescents under 18 years of age because safety and effectiveness in the pediatric population have not been established. Older adults may use the medicine, but caution is advised during initial dosing due to a higher risk of postural hypotension. Patients with severe hepatic (liver) impairment are not recommended to use the medicine due to a lack of clinical data, while those with renal impairment typically require no dosage adjustment.

Conditional Use and Special Status

Before initiating treatment for BPH, the possibility of prostatic carcinoma must be ruled out. The medication is generally not recommended during pregnancy unless the potential benefit clearly outweighs the risk. Caution is advised for breastfeeding mothers, as it is unknown if the medicine is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

The interaction profile for Tai Le (Terazosin hydrochloride) is officially documented by government regulators and focuses primarily on the risk of additive effects on blood pressure and changes to the drug's systemic exposure.

Classification	Interacting Agents and Outcome	Regulatory Restriction
Contraindicated	Vardenafil (PDE5 Inhibitor), Yohimbe (Herbal)	Co-administration is formally prohibited due to the risk of severe, symptomatic hypotension.
Pharmacodynamic	Other Antihypertensives, PDE5 Inhibitors (e.g., Sildenafil)	Concomitant use may result in additive blood pressure lowering effects.
Pharmacokinetic	Verapamil (Calcium Channel Blocker)	Co-administration is documented to increase the systemic exposure (plasma concentration) of Terazosin.

Timing and Substance Constraints

Specific timing rules are mandated for certain combinations. Doses of Sildenafil greater than 25, mg must be administered at least four hours apart from Terazosin to mitigate the risk of adverse events. Additionally, blood pressure lowering medications must be withheld for 24 hours prior to administration of chemotherapeutic doses of Amifostine. Use with alcohol may increase the risk of hypotensive effects. Regulatory documents note that the effects of liver dysfunction on Terazosin's pharmacokinetics are not fully elucidated, and no specific dosage recommendations for hepatic impairment are provided.

Mechanism of Action

Molecular Mechanism: Alpha-1 Adrenergic Receptor Blockade

Tai Le, which contains Terazosin, acts as a competitive antagonist that blocks all subtypes of the post-synaptic alpha-1 adrenergic receptors (alpha1) found on smooth muscle cells. This targeted interaction prevents the sympathetic neurotransmitter, Norepinephrine, from binding, thereby inhibiting the signal cascade that commands the muscle to contract. This molecular action defines the drug’s role as a modulator of the sympathetic nervous system signaling pathway.

Physiological Consequences: Decrease in Smooth Muscle Tone

The primary effect of this blockade is the simultaneous decrease in smooth muscle tone across two distinct areas. In the peripheral blood vessels, the vasocontracting signal is suppressed, leading to widespread vasodilation and the establishment of a reduced Systemic Vascular Resistance (SVR). Concurrently, the alpha1 blockade causes the smooth muscles of the prostate capsule and bladder neck to relax, reducing the dynamic pressure exerted on the urinary outflow tract. Beyond this primary role, the molecule also engages in alpha1-independent mechanisms, including the activation of the glycolytic enzyme Phosphoglycerate Kinase 1 (PGK1), which modulates cellular energy pathways.

Dosage and Administration Information

Tai Le, containing the active ingredient Terazosin hydrochloride, is an oral medication administered exclusively as a capsule. The official administration protocol is designed for long-term use and requires a strict, stepwise titration to establish the appropriate daily dosage.

Official Dosing and Frequency

Treatment must be initiated with the lowest official dose of 1 mg, taken once daily at bedtime. This initial nighttime timing is a fundamental procedural instruction. The capsule can be taken either with or without food and must be swallowed whole. Following initiation, the dose is gradually increased, or titrated, at controlled intervals—typically weekly or bi-weekly—to reach the desired response. The common maintenance range is 1 mg to 5 mg once daily, with the maximum labeled daily dose being 20 mg.

Administration Conditions

For specific patient groups, it is specified that no dose adjustment is necessary for older adults or individuals with renal impairment. A key procedural rule governs missed or interrupted treatment: if therapy is discontinued for several days or longer, treatment must be re-initiated by returning to the 1 mg once-daily starting dose. If a single dose is missed, users should simply resume their schedule with the next dose; doubling the next dose is not part of the protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tai Le

Tai Le refers to two different products that have been studied in research: the prescription pharmaceutical Terazosin hydrochloride (an alpha-blocker) and the Tai-Kang-Ning capsule (a Traditional Chinese Medicine formula). The evidence for these agents is discussed separately below.

Evidence for use in Benign Prostatic Hyperplasia (BPH) Symptoms (Terazosin)

Research examining the alpha-blocker agent for BPH includes Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies were used in research exploring how symptoms change over time in adult men with symptomatic BPH. Studies monitored patient-reported outcomes describing perceived discomfort related to the lower urinary tract and objective outcomes related to functional imbalance, such as maximum urinary flow rate.

Research describes patterns where trials monitored changes in symptom scores and measures related to objective urinary flow rate across various short- and intermediate-term periods. The reported observations for short- to intermediate-term use were described in systematic reviews and trials. Research also describes that these studies have included populations with co-existing essential hypertension, providing context for blood pressure measurements alongside the urological outcomes.

Evidence for use in Essential Hypertension (Terazosin)

Studies for the agent’s use in managing high blood pressure primarily involve RCTs and retrospective analyses. Research examined outcomes related to systemic or functional imbalance, specifically the change in systolic and diastolic blood pressure (SBP/DBP). Findings indicate that studies reported measurable changes in blood pressure across the 24-hour dosing interval. Analysis of data from these large trials was associated with certain cardiovascular event patterns as described by research.

Evidence for use in Acute Heroin Withdrawal Syndrome (Tai-Kang-Ning)

The research foundation for the herbal formulation focuses on conditions associated with acute or disruptive episodes. The evidence is derived primarily from a limited number of short-term, regional RCTs. Studies explored outcomes related to physical discomfort, such as changes in withdrawal symptom severity scores and related anxiety scores. Research highlights changes measured during the study period, reporting how symptoms evolved in the observed populations during the acute phase. Certainty remains low for this evidence base due to modest sample sizes and the short duration of the available trials.

What is Still Uncertain about the Evidence Base

The research landscape clarifies what has been studied and what remains uncertain. For the alpha-blocker (Terazosin), uncertainty primarily relates to the long-term duration of outcomes in BPH and the long-term evidence of comparative outcomes against newer antihypertensive agents. For the herbal formula (Tai-Kang-Ning), comparative evidence is lacking, and the data do not establish long-term post-acute outcomes or sustained measures of dependency.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tai Le (FAQ)

Q: How does Tai Le compare to similar prescription drugs?

Regulatory information indicates that Tai Le, which is an alpha-1 blocker, has blood pressure lowering effects that are similar in magnitude to the alpha-blocker prazosin. Regulatory data defines this medication by its specific mechanism of action, which is distinct from other classes of drugs like diuretics.

Q: What are the most common side effects people report when taking Tai Le?

Regulatory documents describe the most frequently observed side effects in clinical trials as including dizziness, headache, and asthenia (weakness or tiredness). Official safety information provides the full spectrum of possible effects.

Q: Do you have to take Tai Le at the same time every day?

The official administration protocol is to take the medicine once daily at bedtime. The labeling includes procedural guidance that taking the medicine at a consistent time each day, as prescribed, helps align with the intended administration schedule.

Q: Can Tai Le cause issues with sleep?

Yes, official adverse event listings include both somnolence (drowsiness or sleepiness) and insomnia (difficulty sleeping) as reported adverse reactions. These reactions are part of the reported safety profile for the medicine.

Q: Will I need to get blood tests while taking Tai Le?

When the medicine is used for BPH, official patient information indicates that a healthcare provider may require blood work, such as a PSA test, as part of monitoring clinical status. Regardless of the indication, regular monitoring of blood pressure is a standard procedural requirement.

Q: What is the total duration of the research trials for Tai Le?

Studies indicate that the blood pressure-lowering effect may be observed within 15 minutes of administration. However, the full clinical benefit for BPH symptoms often requires a longer period, typically taking four to six weeks or more to become fully established.

Q: Can I stop taking Tai Le suddenly?

Official patient instructions contain warnings about the risks of discontinuing this medicine without consulting a healthcare professional. If therapy is interrupted for several days or longer, the administration protocol requires that treatment must be restarted at the lowest initial dose.

Q: Is it normal to feel a bit dizzy when starting Tai Le?

Yes. Regulatory warnings highlight that this medicine can cause a sudden drop in blood pressure, known as hypotension. This may cause dizziness or lightheadedness, and is most likely to occur after the first few doses or after the dosage has been increased.

Q: Does Tai Le interact with antidepressants or anxiety medicines?

This medicine may interact with any agent that affects blood pressure, which may include certain medications for mood or anxiety. It is stated that a healthcare provider must be informed about all concomitant use of prescription and over-the-counter medicines.

Q: What are the risks of long-term use of Tai Le?

Clinical studies show that the medicine is generally well tolerated over long periods. However, regulatory documents indicate that continuous administration requires regular medical monitoring to reduce the potential for complications, such as low blood pressure.

Q: Does Tai Le require a special storage temperature?

Yes, the capsules must be stored at controlled room temperature, which is typically between 15 C and 30 C (59 F and 86 F). The medication should also be protected from excess moisture and light.

Q: Is Tai Le used for pain relief?

No. The medicine is officially indicated only for the treatment of symptomatic benign prostatic hyperplasia (BPH) and high blood pressure (hypotension). It is not indicated for general pain relief.

Q: Can Tai Le be taken with common over-the-counter pain relievers?

Official warnings specify that a healthcare provider should be consulted before using certain over-the-counter pain relievers. This is particularly important if the medicine is being used for high blood pressure, as some drugs, like NSAIDs, may counteract the blood pressure-lowering effects.

Q: How long does it typically take to start feeling the effects of Tai Le?

Blood pressure effects can begin to decrease within 15 minutes of administration. However, for the treatment of BPH, the full clinical benefit is achieved gradually and may take four to six weeks or longer.

Q: Is it true that Tai Le can make you feel tired?

Yes, fatigue and tiredness are commonly reported in regulatory documents under the adverse reaction term 'asthenia.' Regulatory documents report that this effect was observed with a higher frequency compared to placebo in clinical trials.

Q: Does Tai Le interact with supplements like Vitamin D or magnesium?

Official patient information states that a healthcare provider must be informed about the use of all substances. This includes all vitamins, mineral supplements, and herbal products, as their potential effects must be reviewed.

Q: Is Tai Le known to cause weight gain?

Weight gain is listed as a rare adverse event in regulatory documents. This effect was reported in less than 1% of patients in clinical trials for both BPH and hypertension.

Q: Can taking Tai Le affect my ability to drive?

Yes. Official warnings state that driving or operating machinery should be avoided for 12 hours after the first dose, after any dose increase, or upon restarting the medicine following an interruption. This is due to the risk of dizziness and fainting.

Q: Is Tai Le a controlled substance?

No, the medicine is classified as a prescription-only drug. It is not listed as a federally controlled substance.

Q: Is Tai Le available as a generic medicine yet?

Yes. The active ingredient, terazosin hydrochloride, is approved by regulatory bodies for marketing as a generic medicine under an Abbreviated New Drug Application (ANDA).

Q: What is the purpose of the black box warning on Tai Le's label?

The specific term 'Black Box Warning' (Boxed Warning) is not present on the official FDA label for this medicine. However, a critical warning is present regarding the risk of severe, sudden drops in blood pressure (hypotension).

Q: Is Tai Le used to treat inflammation?

No. The medicine's effect is achieved through blocking alpha-1 adrenergic receptors, which primarily causes smooth muscle relaxation. It is not officially indicated for treating inflammatory conditions.

Q: How long does Tai Le stay in your system after stopping treatment?

The time it takes for the concentration of the medicine in the body to be reduced by half, known as the elimination half-life, is approximately 12 hours.

Q: Where can I find the official prescribing information for Tai Le?

The complete, official prescribing information can be accessed through government-run resources. These include the NIH DailyMed website, the FDA-approved label, and product monographs from national health authorities.

Q: Is it common for Tai Le to cause headaches?

Yes, headache is listed as one of the commonly reported adverse reactions in the official safety documents for this medicine.

Q: How is Tai Le eliminated from the body?

According to official drug information, the medicine is eliminated from the body primarily through two routes: approximately 60% of the dose is excreted via the feces and approximately 40% is excreted via the urine.

How should Tai Le be stored and disposed of?

Storage and Stability Constraints

Tai Le (Immune Globulin Injection) must not be frozen; solutions that have been frozen should not be administered. Prior to use, the solution must be allowed to reach ambient room temperature. The product should be visually inspected for particulate matter and discoloration; do not use the solution if it appears turbid or discolored. The vial is intended for single use only and contains no preservative. Once the vial is entered, the solution must be used promptly, and partially used vials must be discarded and not stored. Do not use the product after the expiration date.

Disposal Instructions

Unused or expired Tai Le should be disposed of by taking it to a drug take-back site or using a drug mail-back program. If these options are unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash, ensuring all personal information is removed from the label.

Tai Le